Novartis is advancing its T-Charge platform, which enables primarily in vivo CAR-T cell expansion, eliminating extended ex vivo culture, with promising early Phase I data from 2021 showing high response rates in DLBCL and multiple myeloma.1
In late 2024, Novartis partnered with Vyriad to co-develop in vivo CAR therapies, with Novartis leading clinical advancement, though no additional recent deals are indicated in available sources.4
No direct recent statements from Novartis CEO Vas Narasimhan specifically confirming ongoing evaluation of in vivo CAR-Ts without new deals were found; Novartis continues internal CAR-T development, including a next-gen platform with process efficiencies, but focuses on autologous approaches over allogeneic.25
Search results lack 2025-2026 news matching the exact query premise, with the most recent relevant partnership from late 2024.4
Sources:
1. https://www.novartis.com/news/media-releases/novartis-announces-t-chargetm-next-generation-car-t-platform-first-human-data-ash-2021
2. https://www.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/pioneers-car-t-cell-and-gene-therapy
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC12885491/
5. https://www.bioprocessintl.com/therapeutic-class/novartis-at-jpm-7-day-car-t-process-an-alternative-to-allogeneic-